Ticker brief
LRMR
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
19
authors 14d
11
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-26 → 2026-07-02 · now +0.45 (−1 bearish … +1 bullish)
Who spoke11
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -0.75 | 5 | +0.28 |
| @BioStocks | C | -0.39 | 3 | +0.45 |
| @OzmosiHealth | C | · | 2 | +0.28 |
| @PersimmonTI | A | -0.32 | 2 | -0.35 |
| @SeegerErik | C | -1.01 | 1 | +0.30 |
| @AlertsAndNews | C | +1.52 | 1 | +0.10 |
| @Optimalinvestme | C | +0.15 | 1 | +0.00 |
| @OpenOutcrier | C | · | 1 | -0.50 |
| @PrismMarketView | C | · | 1 | -0.35 |
| @Pharmdca | C | -1.50 | 1 | +0.55 |
| @Quantumup1 | C | -1.95 | 1 | +0.45 |
Recent signals19of 19 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @Quantumup1 | +0.45 | H.C. Wainwright assumed LRMR coverage at Buy with $10 PT and launch/sales forecasts. | · | tweet ↗ |
| 2026-07-02 | @BioStocks | +0.45 | HCW initiated LRMR with Buy and $10 price target. | · | tweet ↗ |
| 2026-06-30 | @semodough | +0.55 | Citi recommends buying LRMR after FDA feedback and sees favorable risk/reward, PT $14. | · | tweet ↗ |
| 2026-06-30 | @BioStocks | +0.35 | Baird maintains Outperform on LRMR with $5 price target. | · | tweet ↗ |
| 2026-06-29 | @semodough | +0.30 | Lists LRMR BLA, trial, launch and PRV milestones through 2027. | · | tweet ↗ |
| 2026-06-29 | @semodough | +0.40 | LifeSci rates LRMR Outperform with $25 PT after FXN and clinical improvement data. | · | tweet ↗ |
| 2026-06-29 | @Pharmdca | +0.55 | Author is holding LRMR and believes good chance drug gets FDA approval. | · | tweet ↗ |
| 2026-06-29 | @OzmosiHealth | +0.50 | Larimar reports positive open-label data and rolling BLA module submission. | · | tweet ↗ |
| 2026-06-29 | @PrismMarketView | -0.35 | Lists premarket gainers and decliners with percentage moves. | · | tweet ↗ |
| 2026-06-29 | @OpenOutcrier | -0.50 | Larimar stock fell sharply after clinical data release. | · | tweet ↗ |
| 2026-06-29 | @PersimmonTI | -0.20 | Brief German comment on LRMR gives weak negative continuation cue. | · | tweet ↗ |
| 2026-06-29 | @PersimmonTI | -0.50 | Highlights anaphylaxis risk for LRMR. | · | tweet ↗ |
| 2026-06-29 | @BioStocks | +0.55 | LRMR reports positive open-label data and first rolling BLA module submission. | · | tweet ↗ |
| 2026-06-28 | @Optimalinvestme | +0.00 | Ticker list with note that the market pulls back at 4pm; stance unclear. | · | tweet ↗ |
| 2026-06-28 | @AlertsAndNews | +0.10 | Announces investor event tomorrow for nomlabofusp regulatory update and long-term study data. | · | tweet ↗ |
| 2026-06-27 | @SeegerErik | +0.30 | Broad A-M ticker list with generic bullish setup/value language. | · | tweet ↗ |
| 2026-06-26 | @semodough | +0.00 | Notes Larimar webcast date and time for June 29, 2026. | · | tweet ↗ |
| 2026-06-26 | @semodough | +0.15 | Larimar announces investor event on nomlabofusp program for Friedreich's Ataxia. | · | tweet ↗ |
| 2026-06-26 | @OzmosiHealth | +0.05 | Larimar announces investor event on Nomlabofusp program. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.